FDA OKs first semi-quantitative blood tests for COVID-19 antibodies

The FDA approves two blood tests developed at Siemens (OTCPK:SIEGY), the ADVIA Centaur COV2G and Attelica COV2G, that estimate the quantity of a patient’s antibodies against the SARS-CoV-2 virus. The semi-quantitative assays are the first such tests approved in the U.S.

Being able to estimate the quantity of antibodies may be useful in determining the degree of immunity against subsequent infection.

All the serology tests approved to date are qualitative, meaning that they detect the presence of antibodies (a “yes/no” result) but not the specific quantities.

https://seekingalpha.com/news/3598675-fda-oks-first-semi-quantitative-blood-tests-for-covidminus-19-antibodies